



Global drug firms now want backdoor patent for genericsPosted AtNavhindtimes.comEven as India is contemplating changes
in the Drugs and Cosmetics Act, multinationals are lobbying
hard for a new clause in the statute that could lead
to a steep rise in medicine prices, experts say.Global
pharmaceutical firms want the government - which proposes
changes in the law in the upcoming parliament session
- to insert a data exclusivity clause to protect their
clinical trial data from infringement by domestic firms. October 16, 2005
|